The present invention describes the use of angiotensin-(1-7) peptide as an anti-cancer therapeutic. Thus, in one embodiment, the present invention comprises a composition to inhibit the growth of cancer cells in an individual comprising a pharmaceutically effective amount of an agonist for the angiotensin-(1-7) receptor to inhibit cancer cell growth or proliferation. Application of a pharmaceutically effective amount of angiotensin-(1-7) or angiotensin-(1-7) receptor agonist is associated with an increase in the expression of genes involved in tumor suppression, apoptosis, and/or cell cycle inhibition, and a decrease the expression of known oncogenes, protein kinases, and/or cell cycle progression genes. Cancers treated using the methods and compositions described herein include cancers having an angiotensin-(1-7) receptor, including, but not limited to, breast and lung cancer.
本发明描述了
血管紧张素-(1-7)肽作为抗癌疗法的用途。因此,在一个实施方案中,本发明包括一种抑制个体体内癌细胞生长的组合物,该组合物包含药学有效量的
血管紧张素-(1-7)受体激动剂,以抑制癌细胞生长或增殖。应用药学有效量的
血管紧张素-(1-7)或
血管紧张素-(1-7)受体激动剂与参与肿瘤抑制、细胞凋亡和/或细胞周期抑制的
基因表达增加以及已知致癌
基因、蛋白激酶和/或细胞周期进展
基因表达减少有关。使用本文所述方法和组合物治疗的癌症包括具有
血管紧张素-(1-7)受体的癌症,包括但不限于乳腺癌和肺癌。